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In the Xenopus oocyte, progesterone triggers M phase Promoting Factor (MPF) activation in a protein synthesis dependent manner. Although the synthesis of the p42
MAPK activator Mos appears to be required for MPF activation, p42
MAPK activity has been shown to be dispensable. To clarify this paradox, we attempted to activate the p42 MAPK pathway independently of Mos synthesis by cloning and using Xenopus H-Ras in the oocyte. We demonstrate that the injection of the constitutively active Xe H-RasV12 mutant induces p42 MAPK and MPF activation through two independent pathways. Xe H-RasV12 induces only a partial activation of p42 MAPK when protein synthesis and MPF activation are prevented. A full level of p42
Introduction
Xenopus oocytes are naturally arrested in prophase of the first meiotic division (prophase I). This block is released by progesterone, triggering the activation of the cdc2-Cyclin B complex or MPF (M phase Promoting Factor) in a post-transcriptional manner. The oocyte completes the first meiotic division and then arrests again in metaphase of the second meiotic cell division (Metaphase II), a process known as meiotic maturation (for review, see Karaiskou et al., 2001) . Progesterone addition induces a drop in cAMP concentration, leading to the inhibition of the cAMPdependent protein kinase (PKA) activity, and subsequently to the synthesis of new proteins, among them Cyclin B1/B4 and the serine/threonine kinase Mos, product of the c-mos proto-oncogene (Frank-Vaillant et al., 1999; Hochegger et al., 2001; Matten et al., 1994; Sagata et al., 1988) . Mos accumulates at the time of germinal vesicle breakdown (GVBD), leading indirectly to p42 MAPK activation, which ultimately phosphorylates RSK (Ribosomal S6 Kinase) (Karaiskou et al., 2001) . Major objectives in the understanding of the progesterone signaling pathway are, first, to identify which proteins could mediate the early steps of the progesterone pathway and second, to understand the relationship between the p42 MAPK pathway and cdc2 activation.
Possible players in the progesterone transduction pathway are the Ras GTPases . Ras proteins cycle between an inactive GDP-bound form and an active GTP-bound form, which are negatively regulated by GAPs (GTPase Activating Proteins). Oncogenic mutations of Ras, such as G12V, render the protein insensitive to GAPs (Bourne et al., 1991) , promoting their constitutive interaction with effector proteins. Microinjection of the oncogenic human HRas in prophase oocyte induces maturation, with a slow GVBD time-course compared to progesterone (Birchmeier et al., 1985) . Despite some contradiction in the literature, it is generally proposed that human oncogenic Ras-induced cdc2 activation would implicate the Raf/MEK/p42 MAPK pathway (Barrett et al., 1990; Carnero et al., 1994; Daar et al., 1991; Fukuda et al., 1994; Nebreda et al., 1993b; Pomerance et al., 1996) .
The physiological role of p42 MAPK in the cdc2 activation pathway is uncertain. Overexpression of either Mos, constitutively active MEK p42 MAPK or RSK in Xenopus prophase oocyte induces cdc2 activation and maturation in the absence of progesterone (Haccard et al., 1995; Huang et al., 1995; Sagata et al., 1989) . Conversely, the injection of Mos anti-sense oligonucleotides inhibits progesterone-induced cdc2 activation (Sagata et al., 1988) , suggesting that Mos is both necessary and sufficient for cdc2 activation. However, in the presence of various inhibitors of p42 MAPK activation, progesterone is able to induce both GVBD and cdc2 activation, suggesting that active p42 MAPK is not essential for entry into meiosis I (Fisher et al., 1999; Gross et al., 2000) . Moreover, when cdc2 activation is prevented by microinjection of p21
Cip1 (a Cyclin-dependent kinase inhibitor), the accumulation of Mos and the activation of p42 MAPK never occur in response to progesterone, demonstrating that these events are under cdc2 control (FrankVaillant et al., 1999) . Altogether, these results suggest that the Mos/p42
MAPK pathway is not a physiological requirement for cdc2 activation but rather depends on cdc2 activation.
To clarify the interplay between the Mos/p42 MAPK pathway and cdc2 activation, we used the Xenopus oncogenic H-Ras protein as an indirect inducer of p42 MAPK . By microinjection into Xenopus oocyte, we demonstrate that the oncogenic form of Xe H-Ras protein activates p42 MAPK through Mos synthesis and a second activator, which could possibly be Raf. It also induces GVBD and cdc2 activation, although independently of both Mos synthesis and p42 MAPK activation.
Results

Xenopus H-Ras cloning and mutagenesis
Xenopus H-Ras cDNA was cloned from a Xenopus oocyte cDNA library and named Xenopus laevis H-Ras (Xe H-Ras) (Figure 1 ). Xe H-Ras protein shares 96% identity with human H-Ras. The seven amino acids that differ between both species are located in the Cterminus half of the protein, outside the GTP binding site and the effector domain, suggesting that the major functions of H-Ras should be conserved from Xenopus to Man. Two well-documented mutations for mammalian HRas were generated. First, Glycine 12 was replaced by Valine, generating a constitutively active mutant referred as Xe H-RasV12. Second, Cys 186 was replaced by a Serine in the V12 mutant to create a double mutant (Xe H-RasV12/S186) unable to associate with membranes. This membrane targeting has been shown to be required for Ras activity (Gelb, 1997) . Recombinant Xe H-Ras proteins were expressed in bacteria, purified and microinjected into prophase oocytes. We analysed their state of hydrophobic post-translational modifications using Triton-X114 phase partitioning. This detergent, water-soluble at 08C, fractionates into aqueous and detergent-enriched phases at 378C. Prenylation/palmitoylation of H-Ras and, consequently, membrane localization of the protein, correlate with its solubility in the detergent phase (Gutierrez et al., 1989) . As shown in Figure 2 , Xe H-RasV12 and Xe H-RasV12/ S186 were recovered exclusively in the aqueous phase immediately after microinjection into oocytes (time 0). Thirty minutes later, Xe H-RasV12 started to accumulate in the Triton-X114 phase. The posttranslational modifications/membrane targeting of Xe H-RasV12 were completed 3 h after injection ( Figure  2 ). This result indicates that Xe H-RasV12 is prenylated/palmitoylated in vivo and, consequently, addressed to membranes. In contrast, Xe H-RasV12/ S186 remained in the aqueous phase during the experiment (Figure 2 ). Figure  3a) . Depending on the female, 2 mM Xe H-RasV12 induced GVBD slightly slower than progesterone does ( Figure 3a) or with the same time-course (see later, Figure 7b ). The GTP-loading did not appear to be a limiting step for Ras action since the injection of a GTP preloaded-form of Xe H-RasV12 did not accelerate the meiotic maturation (data not shown). All experiments described hereafter were performed using 2 mM of recombinant Xe H-Ras. Interestingly, wild-type Xe H-Ras was also able to induce GVBD although with a much lower efficiency (data not shown).
To further study the efficiency of Xe H-Ras as a meiotic inducer, prophase oocytes were incubated in the presence of progesterone or microinjected either with Xe H-RasV12 or Xe H-RasV12/S186. In contrast to progesterone and Xe H-RasV12, Xe H-RasV12/S186 did not induce GVBD (Figure 3b ). To evaluate cdc2 activation, we analysed Cyclin B2 phosphorylation state by Western blotting (Figure 3b ). Cdc2 activation is correlated with a change in the electrophoretic mobility of its regulatory partner, Cyclin B2 (Taieb et al., 1997 ). An electrophoretic shift of Cyclin B2 was observed after Xe H-RasV12 injection and progesterone addition but not after Xe H-RasV12/S186 injection ( Figure 3b ). Oocyte extracts were also immunoblotted with an anti-phospho-ERK antibody known to recognize only the active p42 MAPK form. In contrast to Xe H-RasV12/S186 injection, progesterone addition and Xe H-RasV12 injection induced the activation of p42 MAPK ( Figure 3b ). The expression level of p42 MAPK did not vary under these conditions, as in all the experiments described below (data not shown, see also Figures 6b and 7a). These results suggest that Xe HRasV12 induces both p42 MAPK and cdc2 activation in Xenopus oocyte as progesterone does and that these events depend on the prenylation/palmitoylation of Xe H-Ras.
Cdc2 and p42
MAPK activation by H-RasV12 are differentially regulated by protein synthesis and cAMP
We investigated whether the activation of cdc2 and p42 MAPK in response to Xe H-RasV12 is dependent on cAMP and protein synthesis, as it is the case for progesterone. Prophase oocytes were incubated in the absence or in the presence of either cycloheximide, a protein synthesis inhibitor, or IBMX, a phosphodiesterase inhibitor. One hour later, progesterone was added or Xe H-RasV12 was microinjected. Oocytes were collected at GVBD time. Cdc2 activity was estimated by histone H1 kinase assay and by Cyclin B2 electrophoretic shift (Figure 4a, b) . As expected, oocytes underwent GVBD and cdc2 was activated in response to progesterone and to Xe H-RasV12 ( Figure  4a ,b). In both cases, cdc2 activation was totally prevented by cycloheximide-or IBMX-treatment (Figure 4a, b) , showing that the activation of cdc2 induced by Xe H-RasV12 depends on the cAMP level and on protein synthesis.
We then analysed the Mos/p42 MAPK /RSK pathway by immunoblotting oocyte lysates with antibodies directed against Mos and active p42 MAPK and also by measuring RSK activity (Figure 4b MAPK and RSK activation when cAMP level is elevated or when protein synthesis is inhibited. These results suggest that, in Xenopus oocyte, Xe H-RasV12 could activate p42 MAPK by two pathways, one being independent of protein synthesis and the other one requiring protein synthesis to allow a full activation of p42 MAPK .
Full activation of p42 MAPK induced by Xe H-RasV12 requires Mos synthesis
In progesterone-stimulated oocytes, Mos is responsible for p42 MAPK activation. Because in Xe H-RasV12-injected oocytes, Mos is never accumulated in the presence of cycloheximide or IBMX, we ascertained that Xe H-RasV12 is able to activate p42 MAPK in the absence of Mos. Anti-sense oligonucleotides directed against Mos mRNA were injected into prophase oocytes treated or not with cycloheximide ( Figure 5 ). Non-sense oligonucleotides were injected as control. One hour later, progesterone was added or Xe HRasV12 microinjected. As expected, Mos accumulation in response to progesterone or to Xe H-RasV12 injection was abolished by the injection of anti-sense oligonucleotides as well as by cycloheximide treatment ( Figure 5 ). As already reported, p42
MAPK activation induced by progesterone was inhibited after Mos antisense oligonucleotides or cycloheximide treatment. In contrast, Xe H-RasV12 was able to activate p42 MAPK in the absence of Mos, although with a lower efficiency ( Figure 5 ). Mos synthesis therefore appears to be required for full p42 MAPK activation induced by Xe H-RasV12 injection. This hypothesis was confirmed by the injection of MBP-Mos that was able to restore a full p42 MAPK activation level in the absence of protein synthesis (data not shown). Raf kinase activity is known to correlate with its phosphorylation, revealed by an electrophoretic mobility shift. As previously shown (Galaktionov et al., 1995) , Raf was phosphorylated in response to progesterone, at time of MPF activation in a protein synthesis-dependent manner ( Figure 5 ). Xe H-RasV12 also led to Raf phosphorylation ( Figure 5 ), but independently of protein synthesis. Under these conditions, the level of Raf protein was slightly reduced ( Figure 5 ). Xe H-RasV12-dependent activation of Raf could account for the partial p42 MAPK activation that takes place in the absence of Mos. As expected, RSK activation was strictly correlated to p42 MAPK activation as judged by its accelerated electrophoretic mobility ( Figure 5 ). These results indicate that Xe H-RasV12 can induce, in vivo, a partial activation of p42 MAPK in the absence of Mos, but that Mos is required for full p42 MAPK activation. Altogether, it can be concluded that Xe H-RasV12 induces p42
MAPK activation through the recruitment of Mos but also through another protein synthesisindependent pathway, most probably involving Raf. This is strikingly different from p42 MAPK activation induced by progesterone that solely depends on Mos synthesis.
Mos-dependent p42 MAPK activation induced by Xe HRasV12 is under the control of cdc2
To directly ascertain that cdc2 activation is not required for p42 MAPK activation induced by Xe HRasV12, we used the CDK inhibitor p21 cip1 , which specifically binds cdc2 in ovo and prevents its activation in response to progesterone (Frank-Vaillant et al., 1999) . p21 cip1 was injected into prophase oocytes. One hour later, oocytes were incubated in the presence of progesterone or microinjected with Xe H-RasV12, and then collected at various times. As expected, in progesterone-treated or Xe H-RasV12 injected oocytes, p21 cip1 prevented GVBD and cdc2 activation, as 
judged by H1 kinase activity and Cyclin B2 immunoblot (Figure 6a ). In the absence of active cdc2, Cyclin B1 was accumulated in response to progesterone, but Mos accumulation was prevented and both p42 MAPK and RSK remained inactive ( Figure 6 ). Therefore, as previously reported (Frank-Vaillant et al., 1999) , cdc2 activity induced by progesterone controls the Mos/ p42 MAPK pathway. Similarly, Cyclin B1 was accumulated in response to Xe H-RasV12 injection even when cdc2 activation was blocked by p21 cip1 (Figure 6a ). Xe H-RasV12 was unable to lead to Mos accumulation in the absence of cdc2 activity (Figure 6b ). Despite the absence of both Mos and active cdc2, a low level of active p42
MAPK was observed 2 h after Xe H-RasV12 injection, in correlation with some RSK activity (Figure 6b,c) . These results show that Mos accumulation, induced by Xe H-RasV12 injection, depends on cdc2 activity. However, as shown in Figures 4 -6 , Mos and cdc2 are dispensable for a small p42 MAPK activation induced by Xe H-RasV12. Interestingly, Raf underwent an electrophoretic mobility shift in response to Xe H-RasV12 injection even in the absence of cdc2 activity (Figure 6b ), again suggesting that it could account for the partial p42
MAPK activation under these conditions.
Mos protein and p42
MAPK are not required for cdc2 activation induced by Xe H-RasV12
We then investigated whether Xe H-RasV12 injection was able to promote cdc2 activation independently of Mos. As shown in Figure 5 , the injection of anti-sense oligonucleotides directed against Mos prevented GVBD and cdc2 kinase activation normally induced by progesterone. Strikingly, GVBD and cdc2 activation were still induced by Xe H-RasV12 injection even in the absence of Mos ( Figure 5 ). Cyclin B1 accumulation also took place normally, clearly indicating that it is not under Mos control ( Figure 5 ). In contrast, all those events were totally abolished when protein synthesis was inhibited by cycloheximide ( Figure 5 ). Therefore, Figure 5 Cdc2 and p42 MAPK activation induced by Xe HRasV12 injection is independent of Mos synthesis. Prophase oocytes were microinjected either with anti-sense (A 7 ) or non-sense (A + ) oligonucleotides directed against Mos, in the presence or in the absence of cycloheximide (CHX). Progesterone (Pg) was added or Xe H-RasV12 was microinjected. At GVBD time, oocytes were homogenized, cdc2 kinase activity was assayed or lysates were immunoblotted with antibodies directed against Cyclin B1, Cyclin B2, Mos, Raf, phospho (active) ERK (pp42 MAPK ) and RSK Figure 6 Xe H-RasV12 injection induces partial p42 MAPK activation and Cyclin B1 accumulation in the absence of cdc2 activation. Prophase oocytes were microinjected or not with recombinant p21 cip1 (Cip1). Eighteen hours later, oocytes were incubated in the presence of progesterone (Pg) or microinjected with Xe H-RasV12. Oocytes were collected at the indicated times. In this experiment, the first pigment rearrangement was observed at 345 min and the well defined white spot corresponding to GVBD occurred at 375 min in both Pg-treated and Xe HRasV12-injected oocytes. To eliminate the possibility that Xe H-RasV12 could lead to cdc2 activation through p42 MAPK and RSK activation, prophase oocytes were incubated in the presence of the MEK inhibitor, U0126. One hour later, progesterone was added or Xe H-RasV12 was microinjected. As expected, p42
MAPK activation was totally prevented by U0126, after either progesterone addition or Xe H-RasV12 injection, although the total level of the protein was unaffected (Figure 7a ). Under these conditions, both progesterone and Xe H-RasV12 induced GVBD although with a slower time course (Figure 7b ) (Gross et al., 2000) . Cdc2 activation was assayed at GVBD time. As shown in Figure 7c , cdc2 was activated in the presence of U0126 in response to progesterone or Xe H-RasV12. P42
MAPK is therefore dispensable for cdc2 activation and GVBD induction in response to Xe H-RasV12.
Discussion
Ras proteins regulate a wide variety of cell functions as molecular switches in the transduction of many extracellular signals. Depending on the cell type and on the extracellular signal, Ras proteins interact with various effectors, including Raf kinase, phosphatidylinositol 3 (PI3) kinase and Ral-GDS (Burgering and Bos, 1995) . In the Xenopus oocyte, injection of human H-RasV12 protein induces activation of cdc2, p42 MAPK and meiotic maturation (for review, see Jessus et al., 1998) . However, there are contradictory data in the abundant literature concerning the pathway induced by human H-RasV12 in the oocyte. We cloned for the first time the Xenopus H-Ras cDNA from an oocyte library, providing the evidence that its mRNA is expressed in this germ cell. The high level of identity between Xenopus and human sequences strongly suggests that this protein could act through similar effectors in both species. We investigated the biological effects of Xenopus H-Ras in oocyte and we demonstrate that the injection of Xe H-RasV12 in this cell induces p42 MAPK and cdc2 activation through two independent pathways.
The physiological trigger of Xenopus oocyte meiotic maturation is progesterone. The progesterone pathway involves the inhibition of PKA activity, which subsequently leads to the synthesis of new specific proteins, required to activate cdc2. One of the maternal mRNA that needs to be translated encodes for Mos (Sagata et al., 1988) that indirectly activates p42 MAPK (Nebreda et al., 1993a; Posada et al., 1993) . The requirement of Mos synthesis and p42 MAPK activation for cdc2 activation is controversial. Experiments based on the use of anti-sense oligonucleotides against Mos led to the conclusion that Mos synthesis is required for cdc2 activation and meiotic maturation (Sagata et al., 1988) . Mos injection induces meiotic maturation and cdc2 activation in a p42 MAPK -dependent manner (Gross et al., 2000; Sagata et al., 1989) . Surprisingly, progesterone can lead to cdc2 activation and GVBD in the absence of p42 MAPK activation (Fisher et al., 1999; Gross et al., 2000) . Moreover, the use of the Cdk inhibitor, p21 cip1 , demonstrated that cdc2 activation is required for Mos accumulation, and consequently for p42 MAPK activation (Frank-Vaillant et al., 1999 MAPK activity in the absence of protein synthesis. These results show that p42 MAPK activation induced by Xe H-RasV12 differs from the progesterone-induced pathway. According to our results and to a previous study (Pomerance et al., 1996) , it implies two mechanisms ( Figure 8) . (1) The first one, never observed after progesterone treatment, induces a partial activation of p42 MAPK independently of protein synthesis. It probably involves Raf ( Figure  8 ). This partial p42 MAPK activation could be explained by a restricted localization or recruitment of Ras targets (the best candidate being Raf), such as the oocyte cortex. (2) A second mechanism is necessary to reach a full level of p42 MAPK activation. This process depends on the synthesis of Mos, itself under the control of active cdc2 (Figure 8 ). This could explain why the full p42 MAPK activation induced by Xe HRasV12 is reached only when cdc2 is activated, as it is the case after progesterone treatment and why it is slow (depending on the number of steps involved in the cdc2-activating pathway and on protein synthesis).
Cdc2 activation and GVBD induced either by Xe HRasV12 or progesterone follow similar time-courses, correlate with Cyclin B1 accumulation and depend on both cAMP drop and protein synthesis. Using the MEK inhibitor U0126 (Gross et al., 2000) , we confirmed that progesterone is able to lead to cdc2 activation in the absence of active p42 MAPK . Conversely, cdc2 activation induced by Xe H-RasV12 injection depends neither on Mos synthesis nor on p42 MAPK activity. Two conclusions can be drawn. First, Xe H-RasV12 induces the activation of p42 MAPK and cdc2 by two independent pathways, although cdc2 contributes to p42 MAPK activation through Mos synthesis (Figure 8 ). Second, in contrast to progesterone, oncogenic Ras activates cdc2 through the synthesis of an unidentified protein which differs from Mos, and that is not connected to the usual p42 MAPK pathway. Importantly, we demonstrate for the first time that cdc2 can be activated when Mos synthesis has been prevented by anti-sense oligonucleotides. Therefore, a Mos-independent pathway leading to cdc2 activation exists in the Xenopus oocyte, suggesting that Mos could not be required for progesterone action.
It has been previously shown that Ras proteins are expressed in prophase oocytes and that the level of the endogenous protein remains stable during meiotic maturation . However, it is not possible to discriminate between the different endogenous forms of Ras (H-, K-and N-) in Xenopus since no specific antibodies are available. We assume that endogenous Ras would not be necessary for the physiological pathway induced by progesterone. First, it has been previously shown that the inhibition of RasGAP blocks Cdc2 activation induced by RasL12 but does not impair progesterone action (Pomerance et al., 1996) . Second, a dominant negative form of H-Ras, the N17 mutant, totally prevents the effects of HRasV12 injection without affecting meiotic maturation induced by progesterone (our unpublished data). Third, the injection of lethal toxin, that glucosylates and inactivates endogenous Ras, is able to induce p42 MAPK and cdc2 activation in the absence of progesterone, suggesting that a pathway independent of active Ras should be functional in the oocyte . Even though Ras is not strictly required for progesterone action, it would participate in this pathway by enhancing p42 MAPK and cdc2 activation. Nevertheless, the identification of the protein synthesized in response to Xe H-RasV12 in the oocyte could represent an important clue in the understanding of the progesterone-signaling pathway. Which in ovo targets of H-Ras are implicated in the activation of cdc2? A variety of candidate Ras protein effectors have been reported in addition to Raf, including principally RasGAP in Xenopus oocyte, PI3 kinase and RalGDS in mammalian cells (Burgering and Bos, 1995; Pomerance et al., 1996; Wolthuis and Bos, 1999) . The inhibition of the SH3 domain of RasGAP has been shown to prevent the activation of both p42 MAPK and cdc2 induced by RasL12 injection (Pomerance et al., 1996) , suggesting that RasGAP is a potential effector of H-ras in the oocyte. It has been reported that PI3 kinase inhibitors do not block human H-RasV12-induced maturation (Lopez-Hernandez and Santos, 1999) , suggesting that H-RasV12 induces cdc2 activation independently of PI3 kinase. Nothing is known on Xenopus RalGDS, a GEF that activates Ral, leading to the activation of other small G proteins MAPK activation through two independent pathways in Xenopus oocytes involved in Golgi vesicle budding for both outside-in and inside-out traffic (Bos, 1998) . Interestingly, oocyte meiotic maturation is accompanied by an arrest in membrane trafficking and the disorganization of the Golgi apparatus (Colman et al., 1985) . Oocyte maturation can be induced either by the inhibition of unknown small G proteins that are targeted by lethal toxin or by the inhibition of protein trafficking (de Smedt et al., 1995; Mulner-Lorillon et al., 1995) . It can therefore be proposed that progesterone-induced cdc2 activation relies on a Ras-dependent reduction of the membrane trafficking through a small G protein that remains to be identified.
Materials and methods
Materials
Xenopus laevis adult females (CNRS, Rennes, France) were bred and maintained under laboratory conditions. [g-32 P]ATP was purchased from DuPont NEN (Boston, MA, USA).
Cloning and mutagenesis of Xenopus laevis H-Ras cDNA
1610
6 pfu of l ZAP Express phages containing a cDNA library from Xenopus laevis oocytes (a kind gift of Dr J Maller) were screened at low stringency with the full length coding sequence of human H-Ras cDNA and at high stringency with Xenopus laevis K-RasB coding sequence cDNA (a kind gift of Dr M Me´chali and Y Ande´ol). Phages hybridizing to the human H-Ras probe, but not to the Xenopus K-Ras probe were selected. PCR-amplified cDNA inserts of individual phages of 2 Kb were screened again using both probes, except that the K-Ras probe was prepared using a 200 bp fragment corresponding to the C-terminus of the coding sequence. cDNA sequences from selected phages were determined using the chain termination method and analysed on an ABI Prism 310 automatic sequencer (Applied Biosystems). A primer complementary to the vector arm was used for the first determination reaction sequence and a custom primer was used for the rest of the coding sequence.
A cDNA fragment corresponding to the Xenopus laevis HRas coding sequence was amplified using the proofreading DNA polymerase Pfu (Stratagene) and custom primers complementary to the 5'-and 3'-ends of the sequence and containing restriction enzymes recognition sequences. Amplified cDNAs were cloned into the bacterial expression vector pUHE 25-2. Both strands of the insert in the resulting plasmid were sequenced as above (Accession Number AY037008). Site-directed mutagenesis of Xenopus laevis HRas was performed using proofreading DNA polymerase.
Xenopus oocyte treatments
Xenopus oocytes were isolated and prepared as described (Jessus et al., 1987) . Oocytes were microinjected with p21 cip1
(1 mM intracellular concentration), various Xe H-RasV12 and Xe H-RasV12/S186 concentrations, or 150 ng per oocyte of non-sense and anti-sense oligodeoxynucleotides directed against Mos mRNA (Frank-Vaillant et al., 1999) . Oocytes were also incubated in the presence of 1 mM progesterone, 100 mg/ml cycloheximide, 1 mM 3-isobutyl-lmethylxanthine (IBMX) or 50 mM U0126 (Promega). Oocyte maturation was monitored following the appearance of a white spot at the animal pole.
Xenopus oocyte extracts
Oocytes were homogenized at 48C in 5 volumes of EB (80 mM b-glycerophosphate, pH 7.3, 20 mM EGTA, 15 mM MgCl 2 , 1 mM dithiothreitol) with protease inhibitors (25 mg/ ml leupeptin and aprotinin, 10 mg/ml pepstatin). Lysates were centrifuged at 15 0006g at 48C for 15 min, supernatants were collected and analysed.
Triton-X114 extraction of Xe H-Ras
The Triton-X114 extraction procedure was adapted from Bordier (1981) . Oocytes microinjected by Xe H-Ras were lysed at 08C in EB supplemented with 1/10 of volume of the Triton-X114 stock. Lysates were centrifuged, supernatants were collected, warmed to 378C for 5 min and centrifuged at room temperature. The upper and the lower phases were separated and analysed by immunoblotting.
Purification of bacterially expressed recombinant proteins p21 cip1 was purified as described in Frank-Vaillant et al. (1999) . Expression of Xe H-Ras in BL21DE3 E. coli strain was induced by 0.5 mM of isopropyl-b-D-thiogalactopyranoside for 3 h. Bacteria were lysed by sonication in 50 mM Tris, pH 7.3, 0.1 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, 5 mM benzamidine, 1 mg/ml lysosyme, 1% NP 40, 1% Triton X-100 and 0.6% CHAPS. Lysate was centrifuged for 1 h at 100 000 g, the supernatant was collected and dialyzed overnight against buffer A (20 mM Tris pH 8.0, 1 mM EDTA, 5 mM MgCl 2 , 1 mM b-mercaptoethanol) and then applied on a 25 ml UnoQ25 anion-exchange column (Bio-Rad) equilibrated in buffer A. After washing with buffer A, proteins were eluted with a 500 ml gradient from 0 to 0.5 M NaCl in buffer A. Fractions were analysed on 15% SDS -PAGE (Laemmli, 1970) . The fractions containing the recombinant protein were concentrated against dry polyethylene glycol and loaded on a Superose 12 gel-filtration column (Pharmacia) equilibrated in buffer A supplemented with 0.1 M NaCl. Fractions containing the recombinant protein were concentrated against dry polyethylene glycol and aliquots were frozen at 7808C.
Western blotting
Samples (equivalent to 2 oocytes) were electrophoresed on 10% Anderson SDS -PAGE (Anderson et al., 1973) and transferred to nitrocellulose membranes (Schleicher and Schuell). The following antibodies were used: sheep polyclonal anti-Cyclin B1 and anti-Cyclin B2 (Frank-Vaillant et al., 1999) , mouse monoclonal anti-Ras (Signal Transduction), mouse monoclonal anti-phospho ERK (New England Biolabs), rabbit polyclonal anti-ERK, goat polyclonal anti-RSK2, rabbit polyclonal anti-Raf, rabbit polyclonal anti-Mos (Santa Cruz Biotechnologies). The secondary HRP-conjugated antibodies (Jackson Immunoresearch, West Grove, USA) were directed against the appropriate species and detected by chemiluminescence (NEN).
Kinase assays
Histone H1 kinase assays were performed on p13 Sepharosebound extracts (3 oocytes equivalent) in the presence of [g-32 P]ATP (0.1 mCi/assay), 100 mM ATP and 0.5 mg/ml histone H1 according to Jessus et al. (1991) .
For RSK assay, lysates of 10 oocytes were immunoprecipitated with the anti-RSK2 antibody and kinase assay was cdc2 activation by Ras in Xenopus oocyte A Dupré et al performed in immunoprecipitates in the presence of 250 mM S6 peptide (a kind gift of Dr J Goris, Belgium) as described (Gross et al., 1999) .
